What records are connected here?
- Evidence lanes
- 3
- Source years
- 18
- Drugs@FDA applications
- 7
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Smaller human trialsHormones · Sexual and reproductive health
Cetrorelix is a synthetic decapeptide that blocks the gonadotropin-releasing hormone (GnRH) receptor, and the active ingredient in Cetrotide.1,2 FDA approved Cetrotide in 2000 to prevent a premature surge of luteinizing hormone (LH) in women undergoing controlled ovarian stimulation for fertility treatment such as IVF.1,2 Its label describes five clinical trials in which 732 women received it, including two well-controlled studies with active comparators.1
| What it is | A synthetic analogue of GnRH with amino acids changed at five positions, which blocks rather than activates the GnRH receptor, according to the label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Cetrotide with an original approval date of August 11, 2000. The cited label has no boxed warning.1,2 |
| Human evidence | Two Phase 2 and three Phase 3 trials in women undergoing ovarian stimulation, including two well-controlled studies with active comparators, described in the label.1 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Cetrorelix is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH) with amino-acid substitutions at positions 1, 2, 3, 6 and 10 that give it GnRH-blocking activity, according to the label.1
In the United States it is the active ingredient of Cetrotide, from EMD Serono, according to Drugs@FDA.2
The label explains that a midcycle surge of LH triggers ovulation. Cetrorelix competes with natural GnRH for its pituitary receptor and so controls the release of LH and FSH.1
The label states that it delays the LH surge, and therefore ovulation, and that its effects reverse after treatment stops. No initial release of the body’s own gonadotropins has been detected, consistent with a blocker.1
The label reports that 732 women aged 19 to 40 were treated with Cetrotide in five trials, two Phase 2 studies and three Phase 3 studies, which excluded women with polycystic ovary syndrome, low ovarian reserve or advanced endometriosis.1
Effectiveness was established separately for two treatment approaches in two well-controlled studies using active comparators, with a third Phase 3 study that had no comparison group, according to the label.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Yes. Drugs@FDA lists Cetrotide, application NDA 021197, with an original approval date of August 11, 2000.2
The Cetrotide label cited here (DailyMed SPL version 18, published September 29, 2025) states that it is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.1
The label has no boxed warning. It states that it should be prescribed by physicians experienced in fertility treatment and that pregnancy must be excluded before starting.1
Its effects in women excluded from the trials, including those with polycystic ovary syndrome, low ovarian reserve or advanced endometriosis, according to the label.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Cetrorelix: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Cetrorelix are a bounded selection, not every registration or paper about Cetrorelix. For the years before Cetrorelix was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Cetrorelix as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Cetrorelix in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Cetrotide for use in controlled ovarian stimulation. The label describes five trials in which 732 women received cetrorelix, including two well-controlled studies with active comparators.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Cetrotide for use in controlled ovarian stimulation. The label describes five trials in which 732 women received cetrorelix, including two well-controlled studies with active comparators.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date November 9, 2026
ClinicalTrials.gov record NCT05326087↗Added to PeptideScanner November 15, 2026Clinical trials · added November 15, 2026
ClinicalTrials.gov record NCT05326087↗Source date November 9, 2026Literature metadata · added November 15, 2026
Comparison of Chitosan-Poloxamer Nanoparticles and Poloxamer-based In-Situ Forming Gel for Nose-to-Brain Delivery of Cetrorelix: In Vitro and Pharmacokinetic Studies in Rats.↗Source date September 24, 2026Regulatory · added November 15, 2026
Drugs@FDA application ANDA218740↗Source date April 29, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
25 of 26 selected trial records include at least one phase value; 26 of 26 include a status value in the retained structured contract.
A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”
22 of 22 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00244452 at 2026-11-15T22:02:39.332Z. Its registry update date was 2008-03-31, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT00439829 at 2026-11-15T22:02:39.332Z. Its registry update date was 2010-05-25, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT00628121 at 2026-11-15T22:02:39.332Z. Its registry update date was 2008-03-04, and PeptideScanner's reviewed identity mapping was cetrorelix.
22 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span August 11, 2000 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05326087 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Literature metadata
PubMed lists PMID 42243608 in AAPS PharmSciTech as Journal Article, Comparative Study, with publication-date metadata of 2026-06-04 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 218740 with status AP dated 2026-04-29, and names cetrorelix acetate among the application record's active ingredients.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05951400 at 2026-11-15T22:02:39.332Z. Its registry update date was 2026-04-15, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02892942 at 2026-11-15T22:02:39.332Z. Its registry update date was 2026-04-03, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06378268 at 2026-11-15T22:02:39.332Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Literature metadata
PubMed lists PMID 36630767 in Journal of pharmaceutical and biomedical analysis as Journal Article, with publication-date metadata of 2022-12-31 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 40386934 in Journal of peptide science : an official publication of the European Peptide Society as Journal Article, with publication-date metadata of 2025-06 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 218061 with status AP dated 2025-06-03, and names cetrorelix acetate among the application record's active ingredients.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04414748 at 2026-11-15T22:02:39.332Z. Its registry update date was 2025-05-31, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06608186 at 2026-11-15T22:02:39.332Z. Its registry update date was 2025-01-22, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05767086 at 2026-11-15T22:02:39.332Z. Its registry update date was 2024-10-15, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026